Partnership supports U.S. commercialization of Diadem’s blood-based Alzheimer’s diagnostic technology

MIAMI, FL and MILAN, ITALY, August 13, 2026 —

Seed Healthcare today announced it has led a strategic investment in Diadem, an Italian company developing blood-based diagnostics for the early detection of Alzheimer’s disease and other neurodegenerative conditions. As lead investor, Seed Healthcare will work alongside Diadem’s leadership to support U.S. commercialization and will hold two seats on the company’s Board of Directors.

The investment expands Seed Healthcare’s portfolio of companies advancing earlier disease detection, precision diagnostics, and technologies that support more proactive healthcare. company is focused on expanding access to blood-based testing that can be more easily integrated into routine clinical care in the U.S.

Diadem, based in Milan, is developing AlzoSure Predict, a proprietary blood-based prognostic technology. The test is designed to identify individuals at risk of progressing to Alzheimer’s disease years before symptoms become clinically apparent through, offering a more accessible and scalable alternative to existing diagnostics. The platform has been clinically validated across more than 900 patient samples, has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and carries CE-IVD marking in Europe.

“Improving prognosis through early detection is one of the biggest opportunities to improve outcomes in Alzheimer’s disease,” said Todd Perman, CEO and GP of Seed Healthcare. “Diadem has developed a platform with the potential to make earlier identification more accessible and practical. We believe the company is well positioned to become a critical part of the future of neurological care.”

“Seed Healthcare brings more than capital,” said Paul Kinnon, who joined Diadem as CEO in 2020 with more than 30 years of experience in global life sciences and diagnostics and now transitions to Chairman of the Board. “Seed’s experience building healthcare businesses and supporting commercialization makes them the right partner as we expand our presence in the United States and continue advancing our platform.”

With key clinical and regulatory milestones in place, Diadem is focused on expanding commercial readiness and preparing for broader adoption.
Together, Seed Healthcare and Diadem are focused on expanding access to blood-based Alzheimer’s diagnostics and supporting broader adoption across the healthcare system. By combining Diadem’s scientific and regulatory progress with Seed Healthcare’s commercialization expertise, the partnership aims to help more clinicians identify patients earlier, support more informed clinical decisions, and strengthen the future of Alzheimer’s care.

About Seed Healthcare
Seed Healthcare is a venture platform focused on advancing healthcare through earlier disease detection, prevention, and commercialization. The firm connects innovation, capital, and providers to help promising healthcare companies scale while improving patient outcomes. Seed invests in companies with meaningful healthcare impact, tangible solutions, and strong commercialization potential, partnering closely with management teams to accelerate growth, expand market reach, and create long-term value.

About Diadem
Diadem is a diagnostics company focused on blood-based solutions for Alzheimer’s disease and other neurodegenerative conditions. Based in Milan, Italy, the company is developing prognostic technologies intended to support earlier detection, improved patient stratification, and broader access to actionable clinical insight.